Amazon leans into the grocer’s premium brand power.
AI prep is changing visits, with doctors wary of misinformation but optimistic about patient education.
Americans across income brackets are cutting spending, rationing meds, and delaying surgery to pay for healthcare costs.
Tighter Medicare Advantage oversight may force insurers to cut perks, exit markets, and leave seniors navigating pricier plans.
The AI portal ties health records and wearables together as daily health conversations top 50 million.
Lilly’s new safety allegations add fuel to lawsuits and FDA actions targeting telehealth sellers of compounded weight loss drugs.
200,000 devices are erased, halting workflows and casting doubt on system security.
Novo drops court fights to secure GLP-1 distribution, which will drive other telehealth brands to weigh pharma deals against legal risk.
Standalone telemental health solutions could benefit from health systems' pursuit of online players that drive referrals.
After White House autism claims, acetaminophen use fell 10% before rebounding, showing how fast trust can waver.
Its $100 million acquisition brings compliant conversations to life sciences CRM amid rising AI adoption.
Parents aren’t as informed on the latest vaccine recommendations, stretching appointments with risk and safety talks.
Many act on their advice—even over doctors’—reshaping how young consumers make decisions about healthcare.
Steady telehealth use among patients supports many market players, but winners will pair Rx access with user experience, AI, and caring providers.
Even with deep discounts, sharper digital marketing will be needed to raise awareness among cash-pay patients.
85% of healthcare orgs plan to boost agentic AI spending and expect near-term savings. Amazon has the technical edge, but may face an uphill battle against entrenched healthcare vendors.
CVS' new Health100 is designed to let consumers—even outside CVS’ network—manage their health more efficiently through tech. But industry adoption may lag.
The FDA’s latest warning wave reinforces ongoing scrutiny of telehealth and pharma promotions.
It rolled out a direct-to-employer payment model aimed at expanding weight loss drug access at work with flat pricing.
Hims & Hers’ former partner plans to continue copycat GLP-1 sales even as FDA investigations and patent lawsuits raise the risks.